Cargando…

In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors

COVID-19, a new strain of coronavirus family, was identified at the end of 2019 in China. The COVID-19 virus spread rapidly all over the world. Scientists strive to find virus-specific antivirals for the treatment of COVID-19. The present study reports a molecular docking study of the stilbenolignan...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cetin, Adnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983322/ https://www.ncbi.nlm.nih.gov/pubmed/33776065 http://dx.doi.org/10.1016/j.cplett.2021.138563

Ejemplares similares

Advances in the Development of SARS-CoV-2 Mpro Inhibitors
por: Agost-Beltrán, Laura, et al.
Publicado: (2022)

Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
por: Papaj, Katarzyna, et al.
Publicado: (2021)

Binding of inhibitors to the monomeric and dimeric SARS-CoV-2 Mpro
por: Tam, Nguyen Minh, et al.
Publicado: (2021)

Fragment-based design of SARS-CoV-2 Mpro inhibitors
por: Teli, Divya M., et al.
Publicado: (2022)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

Potential inhibitors for SARS-CoV-2 Mpro from marine compounds
por: Tam, Nguyen Minh, et al.
Publicado: (2021)

Hemi-Babim and Fenoterol as Potential Inhibitors of MPro and Papain-like Protease against SARS-CoV-2: An In-Silico Study
por: Alzamami, Ahmad, et al.
Publicado: (2022)

Studies on antiviral resistant SARS-CoV-2 Mpro mutants
por: Esler, Morgan A., et al.
Publicado: (2023)

De Novo design of potential inhibitors against SARS-CoV-2 Mpro
por: Li, Shimeng, et al.
Publicado: (2022)

Phytocompounds as potential inhibitors of SARS-CoV-2 Mpro and PLpro through computational studies
por: Rudrapal, Mithun, et al.
Publicado: (2022)

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
por: Farhat, Ameny, et al.
Publicado: (2022)

Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
por: Hassam, Muhammad, et al.
Publicado: (2022)

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study
por: Baig, Mohammad Hassan, et al.
Publicado: (2021)

Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach
por: Biembengut, Ísis Venturi, et al.
Publicado: (2020)

Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study
por: Prajapati, Jignesh, et al.
Publicado: (2022)

Discovering potent inhibitors against the Mpro of the SARS-CoV-2. A medicinal chemistry approach
por: Mehmood, Aamir, et al.
Publicado: (2022)

Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay
por: Narayanan, Anoop, et al.
Publicado: (2022)

Exploration of SARS-CoV-2 Mpro Noncovalent Natural Inhibitors Using Structure-Based Approaches
por: Duong, Cuong Quoc, et al.
Publicado: (2023)

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir
por: Gammeltoft, Karen Anbro, et al.
Publicado: (2023)

Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro
por: Yadav, Ruchi, et al.
Publicado: (2022)

β-Blockers bearing hydroxyethylamine and hydroxyethylene as potential SARS-CoV-2 Mpro inhibitors: rational based design, in silico, in vitro, and SAR studies for lead optimization
por: Hamed, Mohammed I. A., et al.
Publicado: (2021)

Evolutionary aspects of mutation in functional motif and post-translational modifications in SARS-CoV-2 3CLpro (Mpro): an in-silico study
por: Gupta, Amit, et al.
Publicado: (2023)

Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study
por: Nawrot-Hadzik, Izabela, et al.
Publicado: (2021)

Using Chou’s 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors
por: Pundir, Hemlata, et al.
Publicado: (2020)

Finding potential inhibitors for Main protease (Mpro) of SARS-CoV-2 through virtual screening and MD simulation studies
por: Ahamed, N. Anis, et al.
Publicado: (2023)

Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds
por: Nguyen, Trung Hai, et al.
Publicado: (2023)

Unbinding ligands from SARS-CoV-2 Mpro via umbrella sampling simulations
por: Tam, Nguyen Minh, et al.
Publicado: (2022)

Identification of SARS-CoV-2 Main Protease (Mpro) Cleavage Sites Using Two-Dimensional Electrophoresis and In Silico Cleavage Site Prediction
por: Miltner, Noémi, et al.
Publicado: (2023)

Exploring potential SARS-CoV-2 Mpro non-covalent inhibitors through docking, pharmacophore profile matching, molecular dynamic simulation, and MM-GBSA
por: Shi, Yunfan, et al.
Publicado: (2023)

Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
por: Bzówka, Maria, et al.
Publicado: (2020)

Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation
por: Guo, Sheng, et al.
Publicado: (2021)

Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening
por: Federico, Leonardo Bruno, et al.
Publicado: (2021)

Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening
por: Zhang, Li-chuan, et al.
Publicado: (2022)

Unsymmetrical aromatic disulfides as SARS-CoV-2 Mpro inhibitors: Molecular docking, molecular dynamics, and ADME scoring investigations
por: Chtita, Samir, et al.
Publicado: (2022)

Synthesis, characterization, computational analyses, in silico ADMET studies, and inhibitory action against SARS-CoV-2 main protease (Mpro) of a Schiff base
por: ŞAHİN, Songül, et al.
Publicado: (2022)

Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro
por: Silva, Rai C., et al.
Publicado: (2021)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
por: Pavan, Matteo, et al.
Publicado: (2022)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

A year in the life of SARS-CoV-2 Mpro: molecular modeling and analysis of clinically observed Mpro variants from the first year of the COVID-19 pandemic
por: Diessner, Elizabeth M., et al.
Publicado: (2022)

Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations
por: Rasool, Nouman, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4ikp6h30pgg4jco2rlp2tgralf